Expression profiling of G2/M phase regulatory proteins in normal, premalignant and malignant uterine cervix and their correlation with survival of patients.
BACKGROUND
Cell regulatory G2/M phase proteins are the key regulators of mitosis and have been reported with abnormal expressions in various malignancies.


OBJECTIVE
To determine the expressions of these proteins in neoplastic uterine cervix tissue.


METHODS
This study evaluates the G2/M phase regulatory protein expression of Cyclin B1, Aurora-B, Pololike kinase 1 (PLK1) and LIM kinase1 (LIMK1) in tissues of 25 normal (control), 16 dysplastic (dysplasia) and 34 neoplastic (cancer) patients of uterine cervix. The expressions of different proteins were obtained by using Western Blot technique.


METHODS
One way analysis of variance (ANOVA), Pearson correlation, Kaplan-Meier and other tests are used for analysis.


CONCLUSIONS
The level of expression of LIMK1 in cervical cancer patients was found to be significantly higher (P < 0.01) than both the controls and dysplasia. The expression of Aurora B and PLK1 in cervical cancer patients was also found to be significantly higher ( P < 0.05) than controls but it did not differ with dysplasia. However, the expression of Cyclin B1 was similar among cervical cancer patients, dysplasia and controls ( P> 0.05). The expression of all the above proteins showed significant ( P < 0.01) and inverse relation with the survival of cancer patients. Among the selected candidate proteins, it was LIMK1 that showed the most positive correlation with the aggressiveness of the disease and negative correlation (r= -0.64; P < 0.01) with the survival of patients.
Department of Radiotherapy, CSM Medical University, Lucknow, India.
Saxena
Mona
M
Singh
Sharad
S
Negi
M P S
MP
Srivastava
Anupam K
AK
Trivedi
Ritu
R
Singh
Urmila
U
Pant
M C
MC
Bhatt
M L B
ML
D000328:Adult; D000368:Aged; D064107:Aurora Kinase B; D064127:Aurora Kinases; D015153:Blotting, Western; D016022:Case-Control Studies; D018797:Cell Cycle Proteins / Q000378:metabolism*; D002455:Cell Division; D056744:Cyclin B1 / Q000378:metabolism; D005260:Female; D016195:G2 Phase; D020869:Gene Expression Profiling; D006801:Humans; D054461:Lim Kinases / Q000378:metabolism; D008875:Middle Aged; D009367:Neoplasm Staging; D011230:Precancerous Conditions / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D011518:Proto-Oncogene Proteins / Q000378:metabolism; D015996:Survival Rate; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000378:metabolism* / Q000401:mortality* / Q000473:pathology; D055815:Young Adult; D002578:Uterine Cervical Dysplasia / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D000097869:Polo-Like Kinase 1
D064107:Aurora Kinase B; D064127:Aurora Kinases; D018797:Cell Cycle Proteins; D056744:Cyclin B1; D054461:Lim Kinases; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins; D000097869:Polo-Like Kinase 1; C576921:AURKB protein, human; C515892:LIMK1 protein, human